Journal of Experimental & Clinical Cancer Research Submission Guide: What to Prepare Before You Submit
Clinical Cancer Research's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Readiness scan
Before you submit to Clinical Cancer Research, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to Clinical Cancer Research
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- Clinical Cancer Research accepts roughly ~20-30% of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach Journal of Experimental & Clinical Cancer Research
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Confirm the manuscript really bridges laboratory insight to clinical relevance |
2. Package | Finalize declarations, ethics, and disclosure sections before upload |
3. Cover letter | Submit only when the translational consequence is visible on first read |
Quick answer: This JECCR submission guide starts with the core level-setting point. Journal of Experimental & Clinical Cancer Research is not just a broad cancer journal. Its official scope repeatedly emphasizes a translational bridge from laboratory to clinic. That means strong cancer biology alone is often not enough. Editors are looking for mechanistic or molecular work that opens a believable path toward prevention, diagnosis, or treatment.
From our manuscript review practice
Of manuscripts we review for high-end translational oncology targets, the most common early failure is a paper that is biologically interesting but still too far from a credible bench-to-bedside story.
JECCR: Key submission facts
Requirement | Details |
|---|---|
2024 JIF | 12.8 |
Quartile | Q1 |
Publisher | Springer Nature |
Publishing model | Open access |
Submission route | Springer Nature online submission system |
Review model | Single-anonymous peer review |
Core editorial identity | Translational oncology from bench to bedside |
What JECCR is actually screening for
JECCR is broad across oncology topics, but it is selective about the kind of cancer story it wants.
Editors are usually asking:
- does this manuscript contain a significant cancer-research advance
- is there a real translational bridge rather than a generic clinical relevance claim
- do the biomarkers, targets, or mechanisms connect credibly to diagnosis, treatment, or resistance
- is the paper strong enough for a broad oncology readership rather than a narrower specialty lane
That is why purely descriptive tumor biology and thinly translational biomarker papers often struggle here.
The journal is broad enough to cover many oncology formats, but the common requirement is that the bridge to diagnosis, treatment, resistance, or patient selection feels structurally tied to the evidence rather than added as hopeful framing.
Before you submit
Pressure-test these points before upload:
- the abstract makes the translational consequence visible early
- the paper shows more than mechanistic novelty inside one isolated model
- the manuscript includes the required Declarations structure and ethics material
- the clinical bridge is supported by data rather than left to discussion language
- the figures make it obvious why this belongs in a broad translational oncology journal
If the manuscript still feels like basic cancer biology looking for a translational label, the fit is weaker than it appears.
What the official materials make explicit
The live journal guidance is unusually clear about what kind of oncology paper belongs here.
Official signal | Why it matters |
|---|---|
The journal seeks significant advances in basic cancer research with a translational bridge from laboratory to clinic | Translational intent is not optional filler here |
Areas of interest include biomarkers, targeted therapies, personalized medicine, tumor immunotherapy, and large-scale tumor characterization | The journal wants clinically meaningful consequence tied to modern oncology questions |
The manuscript must include a Declarations section with the required subheadings | Package discipline matters on first submission |
The journal operates single-anonymous peer review | Authors should prepare a submission that is robust to direct expert scrutiny |
The journal is open access and built for broad visibility | The readership case should be broad enough to justify the venue |
The practical implication is that JECCR wants more than "interesting cancer biology." It wants a paper that already behaves like translational oncology.
It also wants operational readiness. At journals with this kind of translational positioning, weak declarations, incomplete ethics language, or late disclosure cleanup can make a manuscript feel less mature than the science itself.
Common failure patterns at this journal
1. The translational bridge is too thin
We often see strong mechanistic work where the clinical implications are plausible but not yet structurally carried by the evidence.
2. The biomarker story is not actionable enough
Large-scale molecular characterization and biomarker studies are in scope, but editors still need a clear reason the work changes oncology thinking or decision-making.
3. The clinical claim outruns the dataset
Papers often lose force when the manuscript asks the reader to believe treatment, resistance, or patient-selection implications that the data only partially support.
Before submission, a translational oncology readiness check can tell you whether the problem is bridge strength, actionability, or journal level.
Readiness check
Run the scan while Clinical Cancer Research's requirements are in front of you.
See how this manuscript scores against Clinical Cancer Research's requirements before you submit.
Cover letter and package checklist
Before you upload, make sure the package already answers these questions:
- what is the translational oncology advance
- how does the paper bridge laboratory findings to diagnosis, therapy, resistance, or patient care logic
- are the ethics, declarations, and disclosure sections complete
- does the abstract show a broad oncology consequence without overclaiming
- why does this belong in JECCR instead of a narrower cancer-biology journal
At this level, the cover letter should argue the translational bridge cleanly. It should not force the editor to infer it.
In our pre-submission review work with manuscripts targeting JECCR
In our pre-submission review work with manuscripts targeting JECCR, three patterns show up repeatedly before peer review begins.
- The biology is real, but the translational bridge is still rhetorical. The paper discusses therapy, diagnosis, or patient impact, but the actual evidence package is still mostly mechanistic.
- The tumor dataset is broad but not yet decision-relevant. We see many omics-heavy or biomarker-heavy papers that are interesting but not yet useful enough for this journal's level.
- The first read hides the oncology consequence. A manuscript can be stronger than it looks if the title, abstract, and first figures bury the clinical or translational point too late.
A JECCR fit and first-read check is useful here because many avoidable misses are about translational positioning rather than fatal flaws in the underlying science.
JECCR versus nearby alternatives
Journal | Best fit | Think twice if |
|---|---|---|
JECCR | Translational oncology with a clear bench-to-bedside bridge | The paper is mostly basic cancer biology or mostly narrow clinical observation |
Cancer Research | Strong mechanistic oncology with a broader laboratory-science center of gravity | The manuscript needs a sharper patient-facing bridge |
Clinical Cancer Research | Translational oncology with stronger clinical-trial or patient-management emphasis | The work is still mostly preclinical |
Narrow specialty cancer journal | Disease-specific or method-specific oncology work for a tighter audience | The manuscript clearly matters across oncology readerships |
The right choice depends on whether the paper's center of gravity is translational consequence or narrower mechanistic depth.
Submit If
- the manuscript delivers a significant oncology advance
- the translational bridge is visible in the evidence package
- the title and abstract surface the consequence early
- the declarations, ethics, and disclosure materials are already complete
- the readership case is broad enough for a first-quartile translational oncology journal
Think Twice If
- the manuscript is mainly basic cancer biology with only a light clinical frame
- the biomarker or target story is interesting but not yet actionable enough
- the strongest claim depends on inference beyond the data
- the broad oncology relevance only appears after a long explanation
Before upload, run a translational-oncology first-read check to see whether the paper truly belongs here.
Frequently asked questions
JECCR uses the Springer Nature submission workflow. The operational route is straightforward, but the manuscript needs to read as true translational oncology rather than basic cancer biology with a weak clinical bridge.
The official aims say the journal seeks significant advances in basic cancer research that offer a translational bridge from laboratory to clinic. Editors are usually screening for both mechanistic value and credible clinical or therapeutic consequence.
Yes. The journal's manuscript-preparation guidance is explicit that submissions must include a Declarations section and the required subheadings. Operational discipline matters here, especially for ethics, data, and disclosure material.
Common reasons include basic cancer papers without a convincing translational bridge, biomarker or omics studies that do not clearly change diagnosis or treatment logic, and manuscripts that claim clinical relevance faster than the evidence supports.
Sources
Final step
Submitting to Clinical Cancer Research?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
Supporting reads
Conversion step
Submitting to Clinical Cancer Research?
Anthropic Privacy Partner. Zero-retention manuscript processing.